Investigating blood levels of phoenixin-14 and heart health in infants of diabetic mothers
Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers
This study is testing if higher levels of a substance called phoenixin-14 in the blood are linked to heart problems in babies born to mothers with diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 1 Day to 5 Days |
| Sex | All |
| Sponsor | Konya City Hospital Academic / other |
| Locations | 1 site (Konya, Karatay) |
| Trial ID | NCT06891586 on ClinicalTrials.gov |
What this trial studies
This study examines the relationship between blood levels of the neuropeptide phoenixin-14 and echocardiographic findings in infants born to diabetic mothers. Researchers hypothesize that elevated levels of phoenixin-14 may correlate with specific heart pathologies observed in these infants. The study involves conducting echocardiographic evaluations alongside measuring serum phoenixin-14 levels to assess potential cardiovascular complications. The findings could enhance understanding of how maternal diabetes affects newborn heart health.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy term infants born to mothers with diabetes.
Not a fit: Infants with congenital heart disease or syndromic appearances may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cardiovascular health in infants of diabetic mothers.
How similar studies have performed: While the role of phoenixin-14 in myocardial repair has been explored in animal studies, this specific investigation in human infants is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Infants of diabetic mothers * Healthy term infants Exclusion Criteria: * Infants whose families did not provide consent * Infants with a syndromic appearance or congenital heart disease
Where this trial is running
Konya, Karatay
- Melek Buyukeren — Konya, Karatay, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Melek Buyukeren — Konya City Hospital
- Study coordinator: Melek Buyukeren
- Email: melekbuyukeren@gmail.com
- Phone: +903323105000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.